Using innate immunity to characterize the host response to microbial invasion in severe sepsis

Future Microbiology

Volumn 3, Issue 2, 2008, Pages 177-189

  Warner, Elizabeth A ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Functional genomics; Host pathogen; Inflammation; Interactions; Sepsis; TLR receptors

Indexed keywords

ANTIBIOTIC AGENT; CELL PROTEIN; PROTEIN NOD; TOLL LIKE RECEPTOR;

ANTIGEN RECOGNITION; BACTERIAL INFECTION; CLINICAL DECISION MAKING; DENDRITIC CELL; DISEASE SEVERITY; FUNCTIONAL GENOMICS; GENOME ANALYSIS; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HOSPITAL PATIENT; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MICROBIAL IDENTIFICATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; IMMUNITY, NATURAL; MODELS, BIOLOGICAL; SEPSIS; SIGNAL TRANSDUCTION;

EID: 47249125741     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.2.177     Document Type: Review

References (73)

1. Thomas L: Notes of a biology-watcher. The lives of a cell. N. Engl. J. Med. 284, 1082-103 (1971).
2. Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320, 584-588 (1986).
3. Bone RC, Balk RA, Cerra FB et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655 (1992).
4. Danai PA, Sinha S, Moss M, Haber MJ, Martin GS: Seasonal variation in the epidemiology of sepsis. Crit. Care Med. 35, 410-415 (2007).
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
6. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
7. Cheng B, Xie G, Yao S et al.: Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit. Care Med. 35(11), 2538-2546 (2007).
8. Castaldo ET, Yang EY: Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus. an emerging fatal problem. Am. Surg. 73, 684-637; discussion 687-688 (2007).
9. Davis SL, Perri MB, Donabedian SM et al.: Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 45, 1705-1711 (2007).
10. Anderson KV, Bokla L, Nusslein-Volhard C: Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42, 791-798 (1985).
11. O'Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353-364 (2007).
12. Janeway CA Jr: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11-16 (1992).
13. Matzinger P: The danger model: a renewed sense of self. Science 296, 301-305 (2002).
14. Hashimoto C, Hudson KL, Anderson KV: The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 52, 269-279 (1988).
15. Poltorak A, He X, Smirnova I et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088 (1998).
16. Medhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
17. Werts C, Girardin SE, Philpott DJ: TIR, CARD and PYRIN: three domains for an antimicrobial triad. Cell Death Differ. 13, 798-815 (2006).
18. Gay NJ, Gangloff M: Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem. 76, 141-165 (2007).
19. Schromm AB, Lien E, Henneke P et al.: Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J. Exp. Med. 194, 79-88 (2001).
20. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ: Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J. Biol. Chem. 274, 17406-17409 (1999).
21. Opitz B, Schroder NW, Spreitzer I et al.: Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kB translocation. J. Biol. Chem. 276, 22041-22047 (2001).
22. Schroder NW, Heine H, Alexander C et al.: Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J. Immunol. 173, 2683-2691 (2004).
23. Ozinsky A, Underhill DM, Fontenot JD et al.: The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl Acad. Sci. USA 97, 13766-13771 (2000).
24. Alexopoulou L, Thomas V, Schnare M et al.: Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8, 878-884 (2002).
25. Takeuchi O, Kawai T, Muhlradt PF et al.: Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13, 933-940 (2004).
26. Leemans JC, Stokman G, Claessen N et al.: Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 115, 2894-2903 (2005).
27. Shigeoka AA, Holscher TD, King AJ et al.: TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J. Immunol. 178, 6252-6258 (2007).
28. Sakata Y, Dong JW, Vallejo JG et al.: Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 292, H503-H509 (2007).
29. Hayashi F, Smith KD, Ozinsky A et al.: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
30. Liaudet L, Szabo C, Evgenov OV et al.: Flagellin from Gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock 19, 131-137 (2003).
31. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-KB by Toll-like receptor 3. Nature 413, 732-738 (2001).
32. Heil F, Hemmi H, Hochrein H et al.: Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
33. Hemmi H, Kaisho T, Takeuchi O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196-200 (2002).
34. Takeuchi O, Hoshino K, Akira S: Cutting edge: TLR2-deficient and MyD88-deficient mice am highly susceptible to Staphylococcus aureus infection. J. Immunol. 165, 5392-5396 (2000).
35. Obonyo M, Sabet M, Cole SP et al.: Deficiencies of myeloid differentiation factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect. Immun. 75, 2408-2414 (2007).
36. Kawasaki K, Ernst RK, Miller SI: 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurtum, modulates signaling through Toll-like receptor 4. J. Biol. Chem. 279, 20044-20048 (2004).
37. Miller MB, Bassler BL: Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165-199 (2001).
38. Portnoy DA: Manipulation of Innate immunity by bacterial pathogens. Curr. Opin. Immunol. 17, 25-28 (2005).
39. Kanneganti TD, Lamkanfi M, Nunez G: Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549-559 (2007).
40. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE: Nod-iike proteins in immunity, Inflammation and disease. Nat. Immunol. 7, 1250-1257 (2006).
41. Girardin SE, Boneca IG, Viala J et al.: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872 (2003).
42. Miao EA, Alpuche-Aranda CM, Dors M et al.: Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via Ipaf. Nat. Immunol. 7, 569-575 (2006).
43. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
44. Martinon F, Tschopp J: Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117, 561-574 (2004).
45. Hugot JP, Chamailliard M, Zouali H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 4ll, 599-603 (2001).
46. Ogura Y, Bonen DK, Inohara N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
47. Kobayashi KS, Chamaillard M, Ogura Y et al.: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307, 731-734 (2005).
48. Zipfel PF, Wurzner R, Skerka C: Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol. Immunol. 44, 3850-3857 (2007).
49. Foster TJ: Immune evasion by staphylococci. Nat. Rev. Microbiol. 3, 948-958 (2005).
50. Opal SM, Cohen J: Clinical Gram-positive sepsis: does it fundamentally differ from Gram-negative bacterial sepsis? Crit. Care Med. 27, 1608-1616 (1999).
51. Leong JR, Huang DT: Ventilator-associated pneumonia. Surg. Clin. North Am. 86, 1409-1429 (2006).
52. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
53. Wu CJ, Lee HC, Lee NY et al.: Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. J. Microbiol. Immunol. Infect. 39, 135-143 (2006).
54. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr. Infect. Dis. J. 22, 686-691 (2003).
55. Rice LB: Antimicrobial resistance in Gram-positive bacteria. Am. J. Infect. Control 34, S11-S19; discussion S64-S73 (2006).
56. Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1, 147-155 (2001).
57. Yoshida T, Tsushima K, Tsuchiya A et al.: Risk factors for hospital-acquired bacteremia. Intern. Med. 44, 1157-1162 (2005).
58. Tanaka H, Mituo T, Yukioka T, Matsuda H, Shimazaki S, Igarashi H: Comparison of hemodynamic changes resulting from toxic shock syndrome toxin-1-producing Staphylococcus aureus sepsis and endotoxin-producing Gram-negative rod sepsis in patients with severe burns. J. Burn Care Rehabil. 16, 616-621 (1995).
59. Ahmed AJ, Kruse JA, Haupt MT, Chandrasekar PH, Carlson RW: Hemodynamic responses to Gram-positive versus Gram-negative sepsis in critically ill patients with and without circulatory shock. Crit. Care Med. 19, 1520-1525 (1991).
60. Feezor RJ, Oberholzer C, Baker HV et al.: Molecular characterization of the acute Inflammatory response to infections with Gram-negative versus Gram-positive bacteria. Infect. Immun. 71, 5803-5813 (2003).
61. Lehmbecher T, Venzon D, de Haas M, Chanock SJ, Kuhl J: Assessment of measuring circulating levels of interleukin-6, Interleukin-8, C-reactive protein, soluble Fcy receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin. Infect. Dis. 29, 414-419 (1999).
62. Vandijck DM, Hoste EA, Blot SI, Depuydt PO, Peleman RA, Decruyenaere JM: Dynamics of C-reactive protein and white blood cell count in critically ill patients with nosocomial Gram positive vs. Gram negative bacteremia: a historical cohort study. BMC Infect. Dis. 7, 106 (2007).
63. Oude Nijhuis CS, Vellenga E, Daenen SM et al.: Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia In neutropenic cancer patients. Intensive Care Med. 29, 2157-2161 (2003).
64. Laudanski K, Miller-Graziano C, Xiao W et al.: Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc. Natl Acad. Sci. USA 103, 15564-15569 (2006).
65. Cobb JP, Mindrinos MN, Miller-Graziano C et al.: Application of genome-wide expression analysis to human health and disease. Proc. Natl. Sci. USA 102, 4801-4806 (2005).
66. Calvano SE, Xiao W, Richards DR et al.: A network-based analysis of systemic inflammation in humans. Nature 437, 1032-1037 (2005).
67. Yu SL, Chen HW, Yang PC et al.: Differential gene expression in Gram-negative and Gram-positive sepsis. Am. J. Respir. Crit. Care Med. 169, 1135-1143 (2004).
68. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA: Human macrophage activation programs induced by bacterial pathogens. Proc. Natl Acad. Sci. USA 99, 1503-1508 (2002).
69. Nau GJ, Schlesinger A, Richmond JF, Young RA: Cumulative Toll-like receptor activation in human macrophages treated with whole bacteria. J. Immunol. 170, 5203-5209 (2003).
70. Biberthaler P, Bogner V, Baker HV et al.: Genome-wide monocytic mRNA expression in polytrauma patients for identification of clinical outcome. Shock 24, 11-19 (2005).
71. Feezor RJ, Baker HV, Xiao W et al.: Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J. Immunol. 172, 7103-7109 (2004).
72. Candel FJ, Grima E, Matesanz M et al.: Bacteremia and septic shock after solid-organ transplantation. Transplant Proc. 37, 4097-4099 (2005).
73. Leaver SK, Finney SJ, Burke-Gaffney A, Evans TW: Sepsts since the discovery of Toll-like receptors: disease concepts and therapeutic opportunities. Crit. Care Med. 35, 1404-1410 (2007).